Alternatively, cisplatin may elicit a change in expression in the CDH1-negative tumor cells (i.e., a reduction in replication rate that contributes to cisplatin resistance and may lead to concomitant re-expression of CDH1). The gene discussed is CDH1; the disease is neoplasm.